Account # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5

Similar documents
Knight Diagnostic Laboratories. Exome Requisition for Proband. Complete Exome Orders Must Include All of the Following:

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

panel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Intellectual Disability Exome Panel Requisition Form

The Next Generation of Hereditary Cancer Testing

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

MNG Exome Sequencing Test Request Form

Movement Disorders Requisition Form

Original Policy Date

MNGenome Sequencing Test Request Form

Genetic Testing for Inherited Conditions

Genomics and Genetics in Healthcare. By Mary Knutson, RN, MSN

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation

Exome Requisition Form

YES. If yes, indicate what types of tumors/polyps and age of onset:

Medical Policy Update

Phosphorus. Diagnostics

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation. Chris Miller, MS, LCGC ARUP Laboratories

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

Neurogenetics Genetic Testing and Ethical Issues

Code CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

TumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

REQUISITION FORM NOTE: ALL FORMS MUST BE FILLED OUT COMPLETELY FOR SAMPLE TO BE PROCESSED. Last First Last First

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Name of person previously tested and relationship:

CANCER GENETICS PROVIDER SURVEY

Comprehensive Test Menu December 2018

KNOWING YOUR FAMILY HEALTH HISTORY COULD SAVE YOUR LIFE!

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

General Approach to Genetic Testing

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Should Universal Carrier Screening be Universal?

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Referring Physician Information Name: (Last, First, Middle):

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Address City State Zip Phone. the hospital/facility:

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Illumina Clinical Services Laboratory

Genetic screening. Martin Delatycki

Clinical Cancer Genetics

PATIENT EDUCATION. carrier screening INFORMATION

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Information for Service Users

Russell-Silver syndrome (RSS)

OncoGeneDx Test Requisition Form (River City)

Lab Prior Authorization

Prior Authorization. Additional Information:

General Approach to Genetic Testing

Fragile X One gene, three very different disorders for which Genetic Technology is essential. Significance of Fragile X. Significance of Fragile X

AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS

Hypertrophy of liver Neonatal hypoglycemia Omphalocele Large for gestational age Other:

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing

MOLECULAR SERVICES. mlabs.umich.edu

Whole Exome Sequencing (WES): Questions and Answers for Providers

Comprehensive Test Menu August 2018

Learn your genetic risk for the most common hereditary cancers.

Genetic Testing for Lynch Syndrome

helpful guide Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X

Management of higher risk of colorectal cancer. Huw Thomas

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome

GHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

Genetic Testing for Neurologic Disorders

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY. Name of Test Turnaround Time Cost CPT codes

Genetic Risk Assessment for Cancer

Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center

Reproductive carrier screening

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Preconception carrier screening. Information for Doctors

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Hereditary Cancer Syndromes

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

BowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Chapter 18 Section 13

MEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)

BRCA Precertification Information Request Form

DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3

Gaucher disease 3/22/2009. Mendelian pedigree patterns. Autosomal-dominant inheritance

Additional new products may become commercially available. This is not meant to be a comprehensive list of all available products or tests.

AnyPanel Requisition Form

Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3 (1138 G>A/C and 1620C>A/G)

Genetic Risk Assessment for Cancer

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Accession: Additional testing information is available at

CHRONIC MYELOGENOUS LEUKEMIA

Transcription:

Knight Diagnostic Laboratories Fax: (855) 535-1329 Email: KDLClientServices@ohsu.edu Shipping: 2525 SW 3rd Ave, Ste 350, Portland, OR 97201 Questions? (855) 535-1522 Molecular Genetics Test Requisition Patient Information Full Name Street Address City, State, Zip Phone DOB / / Fax Male Female ID/MRN # Hospital In-Patient Yes No Ordering Physician Information Full Name NPI Office/Facility Name Address City, State, Zip Phone Account # Notes Fax Physician Signature Date Send additional copies of test results to: Physician Name Physician Phone Fax Physician Name Physician Phone Fax Billing Information Self Pay Bill Insurance Bill Client Attach Copy of Insurance Card or Billing Face Sheet Invoice will be sent to Client Account and Address Listed Above Primary Insurance Name Primary Policy # Primary Group # Preauthorization # Relation to Insured Medicaid Medicare Self Child Spouse Other Secondary Insurance Name Secondary Policy # Secondary Group # Preauthorization # Relation to Insured Medicaid Medicare Self Child Spouse Other Clinical Information Amniocytes, Cultured Amniotic Fluid, Direct Blood Spots DNA from* CVS, Direct CVS, Cultured Whole Blood Saliva Tissue Other Specimen Type Date of Specimen Collection / / Time of Specimen Collection : : ICD-10 (required) African American Alaska Native Asian Family History / Pedigree Diagnosis Caucasian/ NonHispanic Hispanic American Jewish, Ashkenazi Jewish (Other) Native American Indian Other: CLIA #38D0881787 Q11 REQ 005.07 page 1 of 5 *DNA extraction must occur in a CLIA-certified lab or a lab meeting equivalent requirements.

Indication for Testing c Family History, Mutation Known: c Yes* c No *If Yes, please complete KNOWN FAMILIAL MUTATIONS c Symptomatic c Possible Diagnosis c Definite Diagnosis c Carrier Testing c Prenatal Testing c Other (Please Specify) Pregnancy: LMP: GMP: c Presymptomatic Testing c Predispositional Testing Known Familial Mutations Please call Client Services at 1 855-535-1522 and provide clinical report if proband testing was performed outside of OHSU. Patient Status: c Symptomatic Name of Gene: Variants to be tested: Name of Proband: Relationship to Proband: OHSU Sample # of Proband: c Asymptomatic * If proband testing was performed outside of OHSU, please provide clinical report. Molecular Diagnostic Tests Next Generation Sequencing Panels 1000 3-MCC Deficiency 1260 Dilated Cardiomyopathy 1004 Agenesis of the Corpus Callosum 1287 Dyslipidemia 1010 Amylotrophic Lateral Sclerosis 1295 Dystonia Panel 1158 Arrhythmogenic Right Ventricular Cardiomyopathy 1291 Epilepsy-Seizures 1085 Bone Marrow Failure 1390 Fabry Disease 1090 Brugada Syndrome 1445 Familial Aneurysm and Aortopathy 1151 Cardiomyopathy 1460 Fanconi Anemia 1167 Catecholaminergic Polymorphic Ventricular Tachycardia 1405 Fatty Acid Oxidation Deficiency 1035 Charcot-Marie-Tooth Syndrome 1465 Gluconeogenesis Disorder 1290 Childhood Epilepsy 1495 Hearing Loss 1275 Cholestasis 1610 Heterotaxia 1277 Ciliopathies 1615 High HDL 1153 Comprehensive Arrhythmias 1625 Holoprosencephaly 1095 Comprehensive Brain Malformation 1499 Hypercholesterolemia 1575 Comprehensive Neuromuscular 1645 Hypertriglyceridemias 1475 Congenital Disorders of Glycosylation 1500 Hypertrophic Cardiomyopathy 1285 Congenital Muscular Dystrophy 1655 Hypolipidemia and Hypocholesterolemia 1293 Congenital Muscular Myopathy 1675 Infantile Epilepsy 1165 Connective Tissue Disorders 1691 Inherited Breast Cancer 1245 Craniosynostosis 1690 Inherited Cancer 1250 Dementia 1692 Inherited Colon Cancer CLIA #38D0881787 Q11 REQ 005.07 page 2 of 5

1693 Inherited Ovarian Cancer 2240 Parkinson s Disease 1694 Inherited Pancreatic Cancer 2250 Platelet Disorders 1725 Joubert Syndrome 2265 Progressive External Ophthalmoplegia 1297 Limb-Girdle Muscular Dystrophy 2270 Propionic Acidemia 2300 Long QT and Short QT Syndromes 2390 Respiratory Chain Deficiency 1860 Low HDL 2405 Rett-Angelman Syndrome 4870 Lynch Syndrome 2590 SOD and Schizencephaly 1990 Macrocephaly 2630 Trifunctional Protein Deficiency 1895 Maturity-Onset Diabetes of the Young 2640 Urea Cycle Disorder 2000 Microcephaly 2810 Wilson s Disease 1135 Migraine and Strokes 2830 X-Linked Intellectual Disabilities, Sequencing and Del/Dup 2055 Movement Disorders 2831 X-Linked Intellectual Disabilities, Sequencing 2100 NBIA Sequencing and Del/Dup 2832 X-Linked Intellectual Disabilities Del/Dup 2101 NBIA Sequencing 2102 NBIA Del/Dup 1159 Non-Compaction Left Ventricular Cardiomyopathy 2135 Noonan and Other Related Disorders Molecular Diagnostic Tests - Single Gene and Targeted Testing 1001 Achromatopsia, CNGA3/CNGB3 Sequencing Angelman Syndrome 1020 SNRPN Methylation and Del/Dup 1030 UBE3A Sequencing 1050 APOL1 Sequencing (exon 6) 1160 CPT1A Targeted Mutation, c.1436c à T (p.p479l) 1150 Connexin 26, GJB2, Sequencing and Connexin 30, GJB6, Deletion Cystic Fibrosis, CFTR 1220 CFTR Screening Mutation Panel (60 mutations) 1224 CFTR Sequencing and Del/Dup 1222 CFTR Sequencing 1226 CFTR Del/Dup 1280 Duchenne/Becker Muscular Dystrophy Del/Dup Familial Adenomatous Polyposis (FAP), APC 1440 APC Sequencing and Del/Dup 1442 APC Sequencing 1444 APC Del/Dup 1420 Factor V Leiden, R506Q mutation Fanconi Anemia 1450 FANCA Sequencing and Del/Dup 1448 FANCA Sequencing 1451 FANCA Del/Dup 1452 FANCC Sequencing 1454 FANCE Sequencing 1456 FANCF Sequencing 1458 FANCG Sequencing CLIA #38D0881787 Q11 REQ 005.07 page 3 of 5

FMR1 related disorders (including Fragile X), FMR1 1480 Fragile X Syndrome, FMR1 1482 FMR1 related Primary Ovarian Insufficiency (POI) 1481 Fragile X Tremor Ataxia Syndrome (FXTAS) Hereditary Hemochromatosis (HH), HFE Mutation 1600 C282Y (heterozygous results are reflexed to H63D) 1602 H63D 1620 Huntington Disease, HTT repeat expansion Disease Specific Physician Statment Required Juvenile Polyposis Syndrome (JPS) 1700 BMPR1A Sequencing 1710 SMAD4 Sequencing Lynch Syndrome (HNPCC) 2028 MLH1 Sequencing 2029 MLH1 Del/Dup 2030 MLH1 Sequencing and Del/Dup 2027 MLH1 Promoter Hypermethylation 2032 MSH2 Sequencing 2033 MSH2 Del/Dup 2034 MSH2 Sequencing and Del/Dup 2036 MSH6 Sequencing 2037 MSH6 Del/Dup 2038 MSH6 Sequencing and Del/Dup 4870 Sequencing Panel (MLH1, MSH2, and MSH6) 5000 Microsatellite Instability (MSI) 4850 Microsatellite Instability (MSI) with IHC Mitochondrial Studies 2020 MELAS 2022 MERRF 2024 NARP Neurodegeneration with Brain Iron Accumulation (NBIA) NBIA NextGen Panel 2100 Sequencing and Del/Dup 2101 Sequencing Only 2102 Del/Dup Only PANK2 (PKAN) 2230 Sequencing and Del/Dup 2231 Sequencing Only 2232 Del/Dup Only PLA2G6 (INAD) 1680 Sequencing and Del/Dup 1682 Sequencing Only 1681 Del/Dup Only 1145 C19orf12 (MPAN), Sequencing 1400 FA2H (FAHN), Sequencing 1550 FTL, Sequencing 1080 WDR45 (Beta-Propeller), Sequencing 1020 Prader Willi, SNRPN Methylation Del/Dup 2290 Prothrombin Related Mutation, G20210A 2130 PTPN11 Sequencing Rett Syndrome (RTT) 2402 MeCP2 Sequencing and Del/Dup 2400 MeCP2 Sequencing 2403 MeCP2 Del/Dup 2404 Atypical, CDKL5, Sequencing Sitosterolemia 2600 ABCG5 Sequencing 2610 ABCG8 Sequencing 2725 von Hippel-Lindau (VHL) Disease, VHL, Sequencing 2026 Mitochondrial Del/Dup 5020 MEN2, RET, Sequencing 2045 MUTYH Associated Polyposis, MUTYH Sequencing 2050 Myotonic Dystrophy, DMPK Repeat Expansion CLIA #38D0881787 Q11 REQ 005.07 page 4 of 5

Other Laboratory Services 1300 DNA Banking Services 2900 Zygosity Testing 1980 Maternal Cell Rule Out 1230 Known Mutation/Familial Variant Targeted Mutation Variant(s) Detail: 1240 Full Gene(s) Analysis Please Specify Gene(s): NOTICE REGARDING MOLECULAR GENETIC TESTING ON DIRECT CVS OR AMNIOTIC FLUID SPECIMENS Maternal cell rule-out testing will be performed on all prenatal specimens received. Please provide maternal blood in addition to the fetal specimen sent for genetic testing. Additional charges apply for the maternal cell rule-out test. All genetic testing performed on direct CVS or Amniotic Fluid specimens will be confirmed on cell cultures prepared by Knight Diagnostic Laboratories. Cell cultures will be prepared from the specimen received. Additional charges apply for confirmatory testing. CLIA #38D0881787 Q11 REQ 005.07 page 5 of 5